Latest revenue
—
as of 2025-12-31
Latest net income
$-35.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANTX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $137.9M
- Enterprise value
- $84.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.69×
- Dividend yield
- 0.0%
- 52-wk high
- $6.91
- 52-wk low
- $1.00
- Beta
- —
- Shares out
- 36.0M
5-year trend
What this company does
Item 1. Business. All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to “AN2,” “we,” “our,” the “Company” or the “Registrant” refer to AN2 Therapeutics. Overview We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to initiate in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone…
AI summary unavailable — showing raw filing excerpt
Generated from ANTX's filing dated 2026-03-17
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the risks described below together with all of the other information contained in this Annual Report, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. Unless otherwise indicated, references in these risk factors to our business being harmed will include harm to our…
AI summary unavailable — showing raw filing excerpt
Generated from ANTX's filing dated 2026-03-17
Profitability
Return on equity
-66.3%
61.1%Return on assets
-56.8%
1.9%Leverage
Debt / equity
0.17×
164.1%Debt / assets
14.4%
140.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q3 2023 2023-09-30 | — | — | $-16.7M | — | — |
Q2 2023 2023-06-30 | — | — | $-15.8M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$54.1K
Net activity
−$54.1K
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANTX
Institutional value
$8.9M
Total shares held
2.6M
Distinct holders
17
-21 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $3.5M | — | New |
| 2 | BlackRock, Inc. | 318.8K | $1.1M | -4.6K (-1.4%) | Trimmed |
| 3 | JANE STREET GROUP, LLC | 303.6K | $1.0M | +285.7K (+1593.1%) | Added |
| 4 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 298.2K | $1.0M | -133.6K (-30.9%) | Trimmed |
| 5 | BANK OF MONTREAL /CAN/ | 260.1K | $889.6K | -161.9K (-38.4%) | Trimmed |
| 6 | VANGUARD FIDUCIARY TRUST CO | 137.7K | $471.0K | — | New |
| 7 | UBS Group AG | 61.4K | $210.0K | +4.7K (+8.3%) | Added |
| 8 | Peapod Lane Capital LLC | 59.9K | $206.9K | -533.5K (-89.9%) | Trimmed |
| 9 | Persistent Asset Partners Ltd | 38.2K | $130.5K | — | New |
| 10 | Hudson Bay Capital Management LP | 34.6K | $118.3K | — | New |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 30.1K | $102.9K | +29.8K (+9826.7%) | Added |
| 12 | CITIGROUP INC | 19.1K | $65.3K | — | New |
| 13 | Private Advisor Group, LLC | 12.5K | $42.8K | -10.0K (-44.4%) | Trimmed |
| 14 | FEDERATED HERMES, INC. | 8.3K | $28.5K | -3.2K (-27.5%) | Trimmed |
| 15 | Vanguard Global Advisers, LLC | 7.3K | $25.1K | — | New |
| 16 | Caitong International Asset Management Co., Ltd | 2.6K | $8.9K | — | New |
| 17 | SBI Securities Co., Ltd. | 201 | $687 | +1 (+0.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANTX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.